• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0
×

Target

Host

Species Reactivity

Species Reactivity

Conjugate

Conjugate

  • Featured Product
  • KD/KO Validated

NRF2, NFE2L2 Recombinant antibody, PBS Only

NRF2, NFE2L2 Recombinant Antibody for WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1I21

Cat no : 80593-1-PBS

Synonyms

NRF2, NFE2L2, HEBP1, Nrf 2, NFE2-related factor 2

Validation Data Gallery

Filter:
  • Western Blot (WB) analysis of various lysates using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    WB analysis using 80593-1-RR (same clone as 80593-1-PBS)

    Untreated and MG132 treated HEK-293 cells were subjected to SDS PAGE followed by western blot with 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of various lysates using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    WB analysis using 80593-1-RR (same clone as 80593-1-PBS)

    Untreated and MG132 treated HepG2 cells were subjected to SDS PAGE followed by western blot with 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of various lysates using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    WB analysis using 80593-1-RR (same clone as 80593-1-PBS)

    Untreated and MG132 treated HeLa cells were subjected to SDS PAGE followed by western blot with 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Western Blot (WB) analysis of various lysates using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    WB analysis using 80593-1-RR (same clone as 80593-1-PBS)

    Untreated and MG132 treated NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:2500 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunoprecipitation (IP) experiment of HeLa cells using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IP experiment of HeLa using 80593-1-RR (same clone as 80593-1-PBS)

    IP result of anti-NRF2, NFE2L2 (IP:80593-1-RR, 4ug; Detection:80593-1-RR 1:700) with HeLa cells lysate 1520 ug. This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunohistochemistry (IHC) staining of human ovary tumor tissue using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IHC staining of human ovary tumor using 80593-1-RR (same clone as 80593-1-PBS)

    Immunohistochemical analysis of paraffin-embedded human ovary tumor tissue slide using 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:400 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunohistochemistry (IHC) staining of human ovary tumor tissue using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IHC staining of human ovary tumor using 80593-1-RR (same clone as 80593-1-PBS)

    Immunohistochemical analysis of paraffin-embedded human ovary tumor tissue slide using 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunohistochemistry (IHC) staining of human pancreas cancer tissue using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IHC staining of human pancreas cancer using 80593-1-RR (same clone as 80593-1-PBS)

    Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:400 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunohistochemistry (IHC) staining of human pancreas cancer tissue using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IHC staining of human pancreas cancer using 80593-1-RR (same clone as 80593-1-PBS)

    Immunohistochemical analysis of paraffin-embedded human pancreas cancer tissue slide using 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunohistochemistry (IHC) staining of Human bowens disease using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IHC staining of Human bowens disease using 80593-1-RR (same clone as 80593-1-PBS)

    Immunohistochemical analysis of paraffin-embedded Brown disease slide using 80593-1-RR (NRF2, NFE2L2 antibody) at dilution of 1:500 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunofluorescence (IF) / fluorescent staining of HepG2 cells using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IF Staining of HepG2 using 80593-1-RR (same clone as 80593-1-PBS)

    Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using NRF2, NFE2L2 antibody (80593-1-RR, Clone: 1I21 ) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunofluorescence (IF) / fluorescent staining of HepG2 cells using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IF Staining of HepG2 using 80593-1-RR (same clone as 80593-1-PBS)

    Immunofluorescent analysis of (-20°C Ethanol) fixed MG132 treated HepG2 cells using NRF2, NFE2L2 antibody (80593-1-RR, Clone: 1I21 ) at dilution of 1:600 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-Phalloidin (red). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Immunofluorescence (IF) / fluorescent staining of HepG2 cells using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    IF Staining of HepG2 using 80593-1-RR (same clone as 80593-1-PBS)

    Immunofluorescent analysis of (-20°C Methanol) fixed HepG2 cells using NRF2, NFE2L2 antibody (80593-1-RR, Clone: 1I21 ) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Flow cytometry (FC) experiment of MCF-7 cells using NRF2, NFE2L2 Recombinant antibody (80593-1-RR)

    FC experiment of MCF-7 using 80593-1-RR (same clone as 80593-1-PBS)

    1X10^6 MCF-7 cells were intracellularly stained with 0.4 ug Anti-Human NRF2, NFE2L2 (80593-1-RR, Clone:1I21) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C). This data was developed using the same antibody clone with 80593-1-PBS in a different storage buffer formulation.

  • Affinity and Kinetic Characterization of 80593-1-RR

    Affinity and Kinetic Characterization of 80593-1-RR

    Biolayer interferometry (BLl) kinetic assays of 80593-1-RR against Human NRF2, NFE2L2 were performed. The affinity constant is 0.191 nM.

☆大好評トライアルサイズ ¥20,000～！ >>> 一次抗体特別価格キャンペーン開催中！

Tested Applications

Recommended dilution

ApplicationDilution
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Product Information

80593-1-PBS targets NRF2, NFE2L2 in WB, IHC, IF/ICC, FC (Intra), IP, Indirect ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Recombinant
Type Antibody
Immunogen NRF2, NFE2L2 fusion protein Ag9489 相同性解析による交差性が予測される生物種
Full Name nuclear factor (erythroid-derived 2)-like 2
Calculated molecular weight 605 aa, 68 kDa
Observed molecular weight 110 kDa, 68 kDa
GenBank accession numberBC011558
Gene symbol NRF2
Gene ID (NCBI) 4780
RRIDAB_2918904
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response (ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress (PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC. As new investigators break into the emerging field of Nrf2 research, confusion regarding the correct migratory pattern of Nrf2 is causing doubts about the accuracy and reproducibility of published results. This letter provides solid evidence that the actually observed molecular weight of Nrf2 is about 70kDa and 95-110 kDa. (PMID: 22703241).